Search

Your search keyword '"Ochoa-Palominos, Alejandra"' showing total 11 results
Start Over Author "Ochoa-Palominos, Alejandra"
11 results on '"Ochoa-Palominos, Alejandra"'

1. Fuentes de variabilidad de la elastografía transitoria hepática y mejoría de su capacidad predicitiva para el diagnóstico de hipertensión portal clínicamente significativa en pacientes con cirrosis compensada

Author

Ochoa Palominos, Alejandra, Rincón Rodríguez, Diego, and Bañares Cañizares, Rafael

Subjects
Endocrinología
Abstract

The most common and severe complication of liver cirrhosis is portal hypertension, which represents the most relevant factor regarding prognosis. Portal hypertension syndrome is defined as an increase in portal pressure gradient above the normal range (1-5 mmHg). In order to develop, esophageal varices, ascites, bleeding, encephalopathy and all other complications associated with this syndrome require a portal pressure gradient above 10 mmHg. The term clinically significant portal hypertension (CSPH) has been coined to define this condition, which is always present in patients with decompensated liver disease. Approximately 50% to 70% of patients with compensated disease have CSPH, which in turn is an independent predictive factor for clinical decompensation. Similarly, esophageal varices are present at the time of cirrhosis diagnosis in 40% of compensated patients and 60% of patients with ascites. The gold standard in assessing portal pressure is the measurement of hepatic venous pressure gradient (HVPG), which is the difference between the wedged (WHVP) and the free hepatic venous pressures (FHVP). This measurement is performed by catheterization of the suprahepatic veins. While this is the most accurate and reliable method currently available, it is an invasive technique requiring specialized materials and personal not available in all health care centers. Therefore, it cannot be routinely used in all units caring for patients with liver diseases...

Published
2016

3. Fuentes de variabilidad de la elastografía transitoria hepática y mejoría de su capacidad predicitiva para el diagnóstico de hipertensión portal clínicamente significativa en pacientes con cirrosis compensada

Author

Rincón Rodríguez, Diego, Bañares Cañizares, Rafael, Ochoa Palominos, Alejandra, Rincón Rodríguez, Diego, Bañares Cañizares, Rafael, and Ochoa Palominos, Alejandra

Abstract

The most common and severe complication of liver cirrhosis is portal hypertension, which represents the most relevant factor regarding prognosis. Portal hypertension syndrome is defined as an increase in portal pressure gradient above the normal range (1-5 mmHg). In order to develop, esophageal varices, ascites, bleeding, encephalopathy and all other complications associated with this syndrome require a portal pressure gradient above 10 mmHg. The term clinically significant portal hypertension (CSPH) has been coined to define this condition, which is always present in patients with decompensated liver disease. Approximately 50% to 70% of patients with compensated disease have CSPH, which in turn is an independent predictive factor for clinical decompensation. Similarly, esophageal varices are present at the time of cirrhosis diagnosis in 40% of compensated patients and 60% of patients with ascites. The gold standard in assessing portal pressure is the measurement of hepatic venous pressure gradient (HVPG), which is the difference between the wedged (WHVP) and the free hepatic venous pressures (FHVP). This measurement is performed by catheterization of the suprahepatic veins. While this is the most accurate and reliable method currently available, it is an invasive technique requiring specialized materials and personal not available in all health care centers. Therefore, it cannot be routinely used in all units caring for patients with liver diseases...

Published
2016

6. Fuentes de variabilidad de la elastografía transitoria hepática y mejoría de su capacidad predicitiva para el diagnóstico de hipertensión portal clínicamente significativa en pacientes con cirrosis compensada

Author

Ochoa Palominos, Alejandra, Rincón Rodríguez, Diego, Bañares Cañizares, Rafael, Ochoa Palominos, Alejandra, Rincón Rodríguez, Diego, and Bañares Cañizares, Rafael

Abstract

The most common and severe complication of liver cirrhosis is portal hypertension, which represents the most relevant factor regarding prognosis. Portal hypertension syndrome is defined as an increase in portal pressure gradient above the normal range (1-5 mmHg). In order to develop, esophageal varices, ascites, bleeding, encephalopathy and all other complications associated with this syndrome require a portal pressure gradient above 10 mmHg. The term clinically significant portal hypertension (CSPH) has been coined to define this condition, which is always present in patients with decompensated liver disease. Approximately 50% to 70% of patients with compensated disease have CSPH, which in turn is an independent predictive factor for clinical decompensation. Similarly, esophageal varices are present at the time of cirrhosis diagnosis in 40% of compensated patients and 60% of patients with ascites. The gold standard in assessing portal pressure is the measurement of hepatic venous pressure gradient (HVPG), which is the difference between the wedged (WHVP) and the free hepatic venous pressures (FHVP). This measurement is performed by catheterization of the suprahepatic veins. While this is the most accurate and reliable method currently available, it is an invasive technique requiring specialized materials and personal not available in all health care centers. Therefore, it cannot be routinely used in all units caring for patients with liver diseases...

Published
2014

8. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].

Author

Giménez-Manzorro Á, García-González X, Rodríguez-González CG, Ochoa-Palominos A, Sanjurjo-Sáez M, and Clemente-Ricote G

Subjects
Antiviral Agents administration & dosage, Antiviral Agents adverse effects, Antiviral Agents economics, Cost-Benefit Analysis, Drug Costs, Drug Therapy, Combination, Emergency Service, Hospital economics, Emergency Service, Hospital statistics & numerical data, Female, Hematologic Diseases chemically induced, Hematologic Diseases economics, Hepatitis C, Chronic economics, Hospitalization economics, Hospitalization statistics & numerical data, Humans, Interferons administration & dosage, Interferons economics, Interferons therapeutic use, Male, Middle Aged, Oligopeptides administration & dosage, Oligopeptides adverse effects, Oligopeptides economics, Proline administration & dosage, Proline adverse effects, Proline economics, Proline therapeutic use, Protease Inhibitors adverse effects, Protease Inhibitors economics, Remission Induction, Retrospective Studies, Ribavirin administration & dosage, Ribavirin economics, Ribavirin therapeutic use, Spain, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy, Oligopeptides therapeutic use, Proline analogs & derivatives, Protease Inhibitors therapeutic use
Abstract

Introduction: Triple therapy with telaprevir or boceprevir has proven to be effective in the treatment of chronic hepatitis C with response rates of up to 88%. However, the treatment may be associated with important adverse effects and a high economic impact., Objective: To assess the cost-effectiveness and safety of triple therapy with telaprevir or boceprevir for the treatment of chronic hepatitis C., Methods: Retrospective observational study. We included all patients who had started treatment with protease inhibitors before July 31(st), 2013. We evaluated sustained virological response, the cost per patient achieving sustained virological response, and the cost of the supportive treatment for adverse events associated with triple therapy., Results: Fifty-nine patients were included; 35 had been treated with telaprevir (59.3%) and 24 with boceprevir (40.7%). Sustained virological response was achieved by 38 (64.4%) patients: 24 (68.6%) patients in the telaprevir treatment arm and 14 (58.3%) patients in the boceprevir treatment arm. The cost per patient with sustained virological response was 43,555 € (95% CI 35,389-51,722 €). There were no statistically significant differences between the overall costs of therapy with telaprevir, 43,494 € (95% CI 34,795 €-55,092 €) versus boceprevir, 42,005 € (95% CI 32,122-64,243€). The mean cost of supportive care per patient was 1,500 €, while the maximum cost was 11,374 €. Due to adverse events, 8 (13.6%) patients required hospital admission, 22 (37.3%) patients attended the accident and emergency department, and 26 (44.1%) patients needed additional medical consultations., Conclusions: The treatment of triple therapy with telaprevir or boceprevir resulted in high cost per patient with sustained virological response. Due to adverse events, a high number of patients required supportive care, whose costs should be added to those of triple therapy., (Copyright © 2015 Elsevier España, S.L.U. and AEEH y AEG. All rights reserved.)

Published
2015
Full Text
View/download PDF

9. Penicillamine induced pseudo-pseudoxanthoma elasticum in a patient with Wilson's disease, which role plays the hepatologist?

Author

Ibáñez-Samaniego L, Ochoa-Palominos A, Catalina-Rodríguez MV, Salcedo-Plaza M, and Clemente-Ricote G

Subjects
Adult, Chelating Agents therapeutic use, Female, Hepatolenticular Degeneration drug therapy, Humans, Penicillamine therapeutic use, Chelating Agents adverse effects, Hepatolenticular Degeneration complications, Penicillamine adverse effects, Pseudoxanthoma Elasticum chemically induced, Pseudoxanthoma Elasticum complications
Published
2015

10. Gastric and duodenal pseudomelanosis: a propos of two cases.

Author

Ochoa-Palominos A, Díaz-Fontenla F, González-Asanza C, Merino-Rodríguez B, Nogales-Rincón Ó, and Menchén-Fernández-Pacheco P

Subjects
Aged, Humans, Male, Middle Aged, Duodenal Diseases pathology, Melanosis pathology, Stomach Diseases pathology
Published
2014

11. [Wilson's disease: clinical spectrum of liver disease].

Author

Ochoa Palominos A, Ibáñez Samaniego L, Catalina Rodríguez MV, Pajares Díaz J, and Clemente Ricote G

Subjects
Adult, Copper, Female, Humans, Liver Diseases diagnosis, Middle Aged, Hepatolenticular Degeneration diagnosis
Abstract

Wilson's disease is a hereditary autosomal recessive disorder of copper metabolism,characterized by copper accumulation in the liver and brain. This rare entity, which has a broad clinical spectrum, is often difficult to diagnose and should therefore always be suspected in patients with liver disease of unclear cause. We describe two types of manifestation of liver disease in two patients; the first developed fulminant hepatic failure requiring urgent liver transplantation and the second showed advanced chronic liver disease and received standard medical treatment. The objective of this clinical observation is to analyze the diagnosis of Wilson's disease in two patients with distinct onset, illustrating the broad clinical spectrum of the disease, and its treatment., (Copyright © 2012 Elsevier España, S.L. and AEEH y AEG. All rights reserved.)

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results